News | August 10, 2021
ALS drug RADICAVA holds promise as it completes four years in US
Nearly 6,000 patients have been treated with the drug since 2017
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The goal for the project is the identification and optimization of anti-viral compounds.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
